Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of CLYM is 9.3 and suggests 84% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell